# Schedule of Accreditation

**issued by**

# United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**8694**

**Accredited to ISO 15189:2022**

## Oxford University Hospitals NHS Foundation Trust

**Issue No:** 012 **Issue date:** 06 June 2025


**Oxford Genetics Laboratories**
**Churchill Hospital**
**Old Road**
**Headington**
**Oxford**
**OX3 7LE**

**Contact: Carolyn Campbell**
**Tel: +44 (0) 1865-226001**
**E-Mail: carolyn.campbell@ouh.nhs.uk**
**Website: www.ouh.nhs.uk/geneticslab**


**Testing performed by the Organisation at the locations specified below**

**Locations covered by the organisation and their relevant activities**

**Laboratory locations:**

| Location details | | Activity | Location code |
|---|---|---|---|
| Oxford Regional Genetics Laboratories<br>Churchill Hospital<br>Old Road<br>Headington<br>Oxford<br>OX3 7LE | **Carolyn Campbell** (contact details above) | Molecular Genetics<br>CytoGenetics | CH |
| Level 4 John Radcliffe University Hospital<br>Headley Way<br>Headington<br>Oxford<br>OX3 9DU | **Carolyn Campbell** (contact details above) | Molecular Haematology | JRH |

DETAIL OF ACCREDITATION

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer<br><br>DNA extraction, quantification and quality check for subsequent in-house analysis (see below), referral to specialist centres and long term storage | Documented in house procedures incorporating manufacturer's instructions (where relevant)<br><br>**Manual and automated DNA extraction and quantification using:** | CH |
| | | **Automated or semi automated extraction:** | **CH** |
| Blood | | Tecan Evo-HSM Robot with ReliaPrep™ Large Volume HT gDNA Isolation kit<br><br>DNA SOP 2011 62, 440, 2005-0159 | |
| Blood<br>Bone Marrow<br>Fresh Tissue<br>Cultured Cells<br>Saliva/Buccal (Oragene collections)<br>Urine | | Promega Maxwell RSC platfrom with Maxwell RSC Blood DNA Kit<br><br>DNA SOP 2011 62, 2005-0159, 607 | |
| FFPE fixed tissue<br>Blood Spots | | Promega Maxwell RSC platfrom with Maxwell RSC FFPE DNA Kit<br><br>DNA SOP 2005-0159, DNA SOP 2019 609, DNA SOP 2019 608 | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS<br><br>Bloods<br>Pleural Effusions<br>Urine | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer | Documented in house procedures incorporating manufacturer's instructions (where relevant)<br><br>**Manual DNA extraction**<br>InstaGENE Matrix<br><br>CYTO SOP 376, DNA SOP 2011 62, 2005-0159 | CH |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from an external source | | DNA Quantification for QC purposes:<br><br>Qubit fluorometer, Nanodrop (ND-2000) and Glomax<br><br>SOPs: CYTO SOP 456, DNA SOP 038, 040, 083. | CH |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from an external source | Detection of specific SNVs and indels (including confirmatory testing)<br><br>[Definitive list as per GEN DOC 926] | **Fragment Analysis**<br>Non-fluorescent PCR amplification followed by restriction enzyme digest using:<br><br>Thermal cycler and gel electrophoresis equipment<br><br>SOPs<br><br>DNA SOP 002, 049 090, 107 | |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from an external source | Presence/absence of DNA regions (including confirmatory testing)<br><br>[Definitive list: GEN DOC 926] | Non-fluorescent PCR amplification followed by agarose gel electrophoresis using:<br><br>Thermal cyclers and gel electrophoresis equipment<br><br>SOPs<br><br>DNA SOP 002. 049, 062, 090, 184 | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer | Documented in house procedures incorporating manufacturer's instructions (where relevant) | |
| Genomic DNA extracted in-house<br>from the sample types listed above<br>or received as primary sample type<br>from external source | Detection of specific SNVs and smallindels (including confirmatory testing)<br><br>[Definitive list as per GEN DOC 926] | Fluorescent PCR amplification followed by Restriction enzyme digest using fluorescently tagged primers<br><br>using:<br><br>thermal cyclers ABI 3730<br>Analysis using Gene Mapper software<br><br>SOPs<br><br>DNA SOP 002, 049 | CH |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from an external source | Detection of expansions including triplet repeats, microsatellite marker analysis, detection of specific SNVs and indels<br><br>[Definitive list :GEN DOC 926] | Fluorescent PCR amplification (including repeat primed PCR and, Devyser) and fragment analysis using commercially available kits or in-house designed assays<br><br>using:<br><br>thermal cyclers ABI 3730<br><br>Analysis using Gene Mapper software<br><br>SOPs<br><br>CYTO SOP 376, DNA SOP 079, 081, 090, 126, 184, 2006-0014, 2010 34, 049, 225 | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer | Documented in house procedures incorporating manufacturer's instructions (where relevant) | CH |
| Genomic DNA extracted in-house<br>from the sample types listed above<br>or received as primary sample type<br>from external source | Quantification of mtDNA copy number<br><br>[Definitive list as per GEN DOC 926] | Real-time PCR using commercially available kits or in-house designed assays<br><br>Using:<br><br>ABI 7500<br><br>Analysis using 7500 software<br><br>SOPs<br><br>DNA SOP 052, 013, 002, GEN SOP 014, 2008 4 | CH |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | Detection and quantification of specific SNVs and indels<br><br>[Definitive list: GEN DOC 926] | <u>Pyrosequencing</u><br><br>using:<br><br>Standard primer design methodology SOP: DNA SOP 731<br><br>in-house methods and Qiagen PyroMark ID System<br><br>SOPs<br>DNA SOP 002, 026, 101, 2010 34 | |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | Targeted detection and quantification of known germline and somatic variants; SNVs, CNVs<br><br>[Definitive list: DOC 926] | **Digital Droplet PCR**<br>Reaction setup using in-house or commercial primer/probe mixes using:<br>Techne PCR Machines, Biorad AutoDG for droplet generation and Biorad QX200 Droplet Reader.<br><br>Analysis using QX Manager Software.<br><br>SOP 665, 666, 667, 941, 944 | CH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS<br><br>Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer<br><br>Detection of nucleic acid sequence variants - SNVs and small indels<br><br>[Definitive list:GEN DOC 926] | Documented in house procedures incorporating manufacturer's instructions (where relevant)<br><br>Sanger sequencing<br><br>using:<br><br>Standard Primer Design methodology:<br><br>Robot: Biomek NX-MC(96)<br>ABI 3730<br>with analysis using Mutation surveyor software and Alamut<br><br>SOPs<br><br>DNA SOP 023, 049, 140, 731, GEN SOP 156 | CH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer | Documented in house procedures incorporating manufacturer's instructions (where relevant) | CH |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | Screening of large targeted single or multigene panels for nucleic acid sequence variants;<br><br>SNVs, indels<br><br>[Definitive list: GEN DOC 926] | Next generation sequencing with target enrichment using; Twist Biosciences generated probes: DNA SOP 0227, 603.<br><br>Using: Veriti PCR Machines, GloMax®-Multi+' Fluorometer, Agilent 2200 Tape Station, Illumina NovoSeq (located within the West Midlands Regional Genetics Laboratory ) or Illumina MiSeq.<br><br>Analysis of DNA sequence data generated internally or externally using an in-house validated bioinformatics pipeline. Variant interpretation using Alamut<br><br>SOPs: DNA SOP 2019 602, , 2019 606, 2020 621, 2020 622, 2020 628, 712 | |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | SNVs, indels and CNVs<br><br>[Definitive list:GEN DOC 926] | Illumina NexteraXT<br><br>Using:<br><br>Dyad PCR Machines Glomax Multi+ Fluorometer, Illumina MiSeq, Agilent 2200 Tape Station<br><br>Analysis of DNA sequence data generated either internally or externally using an in-house validated bioinformatics pipeline<br><br>DNA SOP 0227, 421, 2015 327, 2019 592 and 2019 593. | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS<br><br>Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer<br><br>SNVs, indels and CNVs<br><br>[Definitive list:GEN DOC 926] | Documented in house procedures incorporating manufacturer's instructions (where relevant)<br><br>SOPHiA Genetics custom panel kit<br><br>DNA SOP 0460, 2015 316, 0227<br><br>Using:<br><br>Veriti (Applied Biosystems) PCR Machines'GloMax®-Multi+' Fluorometer, Illumina MiSeq, Agilent 2200 Tape Station<br><br>Analysis using the Sophia Genetics bioinformatics DDM pipeline<br><br>Variant interpretation using Alamut<br><br>DNA SOP 528, 2015 327. | CH |
| Genomic DNA extracted in-house from the sample types listed above or received as primary sample type from external source | Detection of whole or partial gene deletions, duplications probe specific SNVs and indels and methylation status | **Multiplex Ligation Probe Analysis (MLPA) and methylation specific MS-MLPA**<br><br>Using:<br><br>Multiplex Ligation-dependant Probe Amplification (MLPA) (using MRC Holland kit) or custom design MLPA (using a kit template supplied by MRC-Holland)<br><br>Methylation specific MLPA kit (MS-MLPA)<br><br>Using<br><br>Thermal cyclers and ABI 3730 with analysis using Coffalyser software<br><br>DNA SOP 2015 374, 050, 128, 204 | CH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS<br><br>Products of conception<br>Biopsies (includes skin)<br>Tissues<br>CSF<br>Pleural Fluid,<br>Ascites<br>Whole Blood<br>Bone Marrow | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer<br><br>G-Banding/Karyotyping<br><br>Detection of chromosomal rearrangements or aberrations arising from: *(e.g)*<br><br>Developmental disorders<br>Reproductive medicine disorders<br>Haematological/Oncology disorders<br><br>(Preparative Pre-examination steps listed first) | Documented in house procedures incorporating manufacturer's instructions (where relevant)<br><br><u>G-Banding/Karyotyping</u><br><br>Manual culturing using commercial media, processing (cell harvesting and slide preparation and banding) of human tissue to provide metaphase cells<br><br>Using:<br><br>Safety cabinets, incubators, centrifuges, hotplate,<br><br>SOPs: CYTO SOP 67, 111, 185, 271, 414<br><br>Analysis:<br><br>Karyotype analysis of metaphase chromosomes light microscopy using:<br><br>Microscopes, Cytovision Image Capture System | CH |
| Products of conception<br>Biopsies (includes skin)<br>Tissues<br>CSF<br>Pleural Fluid,<br>Ascites<br>Whole Blood<br>Bone Marrow<br>Urine<br>Buccal swabs | (Preparative Pre-examination steps for FISH) | Direct preparation (without culture) to provide fixed interphase cells<br><br>and<br><br>Processing of FFPE sections for material suitable for FISH<br><br>Using:<br><br>Hotplate, fume hood, water bath, and Hybrite/Thermobrite<br><br>SOPs 67, 132, 271, 340, 352 | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND BODY FLUIDS<br><br>Fixed cultured cells as prepared as detailed in G-banding/Karyotyping section<br>Fixed uncultured cells<br>FFPE sections | Genomic analysis for the purpose of clinical diagnosis of rare disease and cancer<br><br>Targeted analysis of the genome for copy number alterations, balanced chromosome rearrangements, mosaicism and formation of gene fusions.<br><br>Using locus specific probes for:<br><br>Translocations and/or inversion<br>Deletions<br>Fusions<br>Copy Number<br><br>[Definitive list:GEN DOC 926] | Documented in house procedures incorporating manufacturer's instructions (where relevant)<br><br>Fluorescence in situ hybridisation (FISH)<br><br>using:<br><br>Hybrite/Thermobrite, UV light box, microfuge fume hood and waterbath.<br><br>FISH analysis by use of fluorescently tagged probes and fluorescence microscopy to detect copy number and spatial location of specific regions of the genome using:<br><br>SOPs CYTO SOP 67, 132, 271, 340, 352, 364, 412, 414<br><br>FISH analysis by use of fluorescently tagged probes and fluorescence microscopy to detect copy number and spatial location of specific regions of the genome<br><br>using:<br><br>Cytovision Image Capture System | CH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND FLUIDS | Molecular genetic analysis for genetic mutations and variants | Procedures documented in manufacturer's equipment manuals in conjunction with documented in- house procedures by the following methods: | JRH |
| Blood<br>Bone Marrow<br>CVS<br>Amniotic Fluid<br>FFPE tissue | | Automated DNA extraction and quantification using the QIAGEN Symphony and in-house procedures:<br>Haem SOP 940<br>HC 2531<br>HC 2271<br>HC 2315 | JRH |
| Blood<br>Bone Marrow | | Semi-automated RNA extraction and cDNA preparation using the QIAGEN Qiacube and in house procedures<br>HC 2302 | |
| Blood<br>Bone Marrow<br>FFPE | | Automated Paramegnetic particle nucleic acid extraction and purification using the Promega Maxwell system;<br>Haem SOP 2599: DNA using AS1321 kit<br>Haem SOP 2608: RNA using AS410 kit<br>Haem SOP 2611: FFPE using RSC FFPE DNA plus kit | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND FLUIDS (cont'd) | Molecular genetic analysis for genetic mutations and variants (cont'd) | Procedures documented in manufacturer's equipment manuals in conjunction with documented in- house procedures by the following methods: | JRH |
| Blood<br>DNA | Somatic myeloid disorder diagnostic gene panel. Mutations in: | NextSeq 550 Next Generation Sequencing and custom designed commercial panel (SeqCap EZ HyperCap (Roche) | |
| | ASXL1 (NM_015338.5), ATRX (NM_000489.3), CBL (NM_005188), CBLB (NM_170662.3), CBLC (NM_012116.3), CSF3R (NM_156039.3), DNMT3A (NM_022552), ETV6 (NM_001987.4), EZH2 (NM_004456.4), HRAS (NM_005343.2), IDH1 (NM_005896.2), IDH2 (NM_002168.2), FLT3 (NM_004119), JAK2 (NM_004972.3), KIT (NM_000222.2), KRAS (NM_033360.2), MPL (NM_005373), NPM1 (NM_002520.6), NRAS (NM_002524.4), PDGFRA (NM_006206.4), PHF6 (NM_032458.2), PTEN (NM_000314), RUNX1 (NM_001754.4), SETBP1 (NM_015338.5), SF3B1 (NM_012433.2), SRSF2 (NM_001195427.1), TET2 (NM_001127208.2), TP53 (NM_000546.5), U2AF1 (NM_001025203.1), WT1 (NM_024426.4) and ZRSR2 (NM_005089.3) | Haem SOP 2623<br>Haem SOP 2621<br>Haem SOP 2618<br>Haem SOP 2619 | JRH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND FLUIDS (cont'd) | Molecular genetic analysis for genetic mutations and variants (cont'd) | Procedures documented in manufacturer's equipment manuals in conjunction with documented in- house procedures by the following methods: | JRH |
| Next Generation Sequencing Data in the form of BAM files, variant lists, and gene- level coverage data received from Oxford Regional Genetics (UKAS 8694) | Rare anaemia diagnostic gene panel. Mutations in:<br><br>ABCB7 (NM_004299.3),<br>ALAS2 (NM_000032.4),<br>ALDOA (NM_000034.3),<br>ANK1 (NM_000037.3),<br>C15orf41 (NM_001130010.1),<br>CDAN1 (NM_138477.2),<br>ENO1 (NM_001428.3),<br>EPB41 (NM_004437.3),<br>EPB42 (NM_000119.2),<br>G6PD (NM_001042351.2),<br>GATA1 (NM_002049.3),<br>GATA2 (NM_032638.4),<br>GCLC (NM_001498.3),<br>GPI (NM_000175.3),<br>GPX1 (NM_000581.2),<br>GSR (NM_000637.3),<br>GSS (NM_000178.2),<br>HK1 (NM_000188.2),<br>KIF23 (NM_138555.2),<br>KLF1 (NM_006563.3),<br>LPIN2 (NM_014646.2),<br>NT5C3A (NM_016489.12),<br>PFKM (NM_000289.5),<br>PGK1 (NM_000291.3),<br>PIEZO1 (NM_001142864.2),<br>PKLR (NM_000298.5),<br>RHAG (NM_000324.2),<br>RPL11 (NM_000975.3),<br>RPL26 (NM_000987),<br>RPL27 (NM_000988.3),<br>RPL35A (NM_000996.2),<br>RPL5 (NM_000969.3),<br>RPL9 (NM_000661.4),<br>RPS10 (NM_001014.4),<br>RPS17 (NM_001021.3) | Analysis and reporting of data only using Alamut Visual and IGV software<br><br>HC 2154<br>HC 2152<br>Haem SOP 2457 | JRH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND FLUIDS (cont'd) | Molecular genetic analysis for genetic mutations and variants (cont'd) | Procedures documented in manufacturer's equipment manuals in conjunction with documented in- house procedures by the following methods: | JRH |
| Next Generation Sequencing Data in the form of BAM files, variant lists, and gene- level coverage data received from Oxford Regional Genetics (UKAS 8694) | Rare anaemia diagnostic gene panel (cont). Mutations in:<br><br>RPS19 (NM_001022.3),<br>RPS24 (NM_033022.3),<br>RPS26 (NM_001029.3),<br>RPS27 (NM_001030.4),<br>RPS29 (NM_001032.4),<br>RPS7 (NM_001011.3),<br>SBDS (NM_016038.2),<br>SEC23B (NM_006363.4),<br>SLC11A2 (NM_000617.2),<br>SLC25A38 (NM_017875.2),<br>SLC2A1(NM_006516.2),<br>SLC4A1 (NM_000342.3),<br>SPTA1 (NM_003126.2),<br>SPTB (NM_000347.5),<br>TMPRSS6(NM_153609.2),<br>TPI1(NM_000365.5). | Analysis and reporting of data only using Alamut Visual and IGV software<br><br>HC 2154<br>HC 2152<br>Haem SOP 2457 | JRH |
| Blood<br>Bone Marrow | BCR-ABL analysis (ALL, CML) Diagnosis and monitoring of MRD (p210, p190 only) | Published Multiplex RT-PCR method using Qiagen, Rotorgene, Commercial QPCR (Qiagen) kit for MRD, Pyrosequencing using QIAGEN Pyromark Q24<br>HC 2301<br>HC 2302<br>HC 2303<br>HC 2304<br>HC 2306 | JRH |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND FLUIDS (cont'd) | Molecular genetic analysis for genetic mutations and variants (cont'd) | Procedures documented in manufacturer's equipment manuals in conjunction with documented in- house procedures by the following methods: | |
| | Acute Leukaemia Diagnosis: | RE-PCR using Biometra Thermocycler | |
| Blood<br>Bone Marrow | FLT-3 D835 | HC 2118 | JRH |
| | NPM1 | In house fragment analysis method using ABI instrumentation<br>HC 2119 | |
| Blood<br>Bone Marrow | Acute Leukaemia MRD monitoring (PML-RARA, Inv16, AML-ETO) | Commercial QPCR (Qiagen) kit for MRD using QIAGEN Rotorgene,<br>HC 2304 | |
| Blood<br>Bone Marrow<br>Tissue | Lymphoma B Clonality (IgH rearrangements) | Commercial (Invivoscribe) fragment analysis using ABI instrumentation<br>Haem SOP 1163 | |
| | Lymphoma T Clonality (TCR re-arrangements) | HC 2268<br>HC 2267<br>Haem SOP 1163 | |
| Blood<br>Bone Marrow | Jak-2 mutation screen (V617F) | In house ARMS-PCR using Biometra thermocycler, Pyrosequencing using the QIAGEN Rotorgene<br>HC 2261 | JRH |
| Blood<br>Bone Marrow | Chimerism STR pattern analysis (Chimerism) to detect mxed samples (e.g. Maternal contamination / Chimerism | Promega Powerplex Fusion commercial kit, and fragment analysis using ABI instrumentation<br>HC 2381<br>HC 2141 | |
| Blood<br>Bone Marrow<br>FFPE | Detecting L265P point mutation of the MYD88 gene | Allelic specific real-time PCR assay using hydrolysis probes<br>ABI Real Time 7500<br>Haem SOP 2468. | |

| Materials/Products tested | Type of test/Properties measured/Range of measurement | Standard specifications/ Equipment/Techniques used | Location |
|---|---|---|---|
| HUMAN TISSUES AND FLUIDS (cont'd) | Molecular genetic analysis for genetic mutations and variants (cont'd) | Procedures documented in manufacturer's equipment manuals in conjunction with documented in- house procedures by the following: | |
| FFPE DNA | EGFR common mutation screen | COBAS 4800 system, RT-PCR and commercial (COBAS) kits Haem SOP 578 | JRH |
| FFPE DNA | BRAF mutation screen (V600E) | COBAS 4800 system, RT-PCR and commercial (COBAS) kits Haem SOP 579 | |
| FFPE DNA | Somatic Cancer 50 gene diagnostic panel. Mutations in: TP53 NM_000546.5, PTEN NM_000314.4, PIK3CA NM_006218.2, PDGFRA NM_006206.4, KRAS NM_004985.3, NRAS NM_002524.4, KIT NM_000222.2, EGFR NM_005228.3, BRAF NM_004333.4. ERBB4, FGFR1, ERBB2, MET, FLT3, FGFR3, GNAS, SMARCB1, CTNNB1, CDKN2A, ABL1, NOTCH1, ATM, PTPN11, SMO, SMAD4, VHL, NPM1, MPL, CSF1R, HRAS, JAK3, AKT1, IDH1, CDH1, FGFR2, SRC, KDR, ALK, JAK2, RB1, MLH1, HNF1A, APC, RET, STK11, FBXW7, EZH2, GNA11, GNAQ and IDH2 | Thermofisher Ampliqseq Next Generation Sequencing commercial panel and Ion Torrent next generation sequencing. Haem SOP 624 Haem SOP 491 Haem SOP 625 HC 2411 HC 2408 | JRH |
| FFPE DNA | Acquired NGS panel using custom AmpliSeq primer pools and S5 Ion Torrent Sequencing DNA -AmpliSeq panel on S5 Ion Torrent | Custom designed Ampliseq Next Generation Sequencing Panels and Ion Torrent Next Generation Sequencing (ThermoFisher). Haem SOP 625 Haem SOP 2657 Haem SOP 491 | |
| END | | | |